GCC Agonist Signal in the Small Intestine

Trial details

Who runs it

University of Wisconsin, Madison

Trial code

NCT05107219

Record updated

7 April 2026

Original description

This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.Read full original descriptionShow less

Pilot Study of GCC Agonists to Identify a Cyclic-GMP Signal in Duodenal Tissue of Volunteers

This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.

Inclusion: Scheduled for clinically indicated esophagogastroduodenoscopy (EGD); Age >= 18 years of age. Note: Because no dosing or adverse event (AE) data are currently available on the use of plecanatide or linaclotide in participants < 18 years of age, children and adolescents are excluded from this study but will be eligible for future pediatric trials, if applicable; Willing to provide mandatory biospecimens as specified in the protocol; Eastern Cooperative Oncology Group (ECOG) performance status =< 2; Not pregnant or breastfeeding, as determined by pregnancy test prior to EGD procedure. Note: The effects of plecanatide and linaclotide on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 2 weeks after discontinuing study agent. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. Breastfeeding should be discontinued if the mother is treated with plecanatide or linaclotide; Ability to understand and the willingness to sign a written informed consent document; Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial; For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated; Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load; Patients on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible.

Exclusion: Prior treatment in the past week with plecanatide, linaclotide, or other agent whose primary mechanism of action is that of a GCC agonist; Use of any other investigational agents =< 12 weeks prior to registration; History of allergic reactions attributed to compounds of similar chemical or biologic composition of plecanatide or linaclotide; Uncontrolled intercurrent illness, or psychiatric illness/social situations that would limit compliance with study requirements; History of gastric bypass, gastric sleeve, or bariatric surgery.

ClinicalTrials.gov NCT05107219